pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,887 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1835Endpoints1421Fierce Biotech742BioSpace733BioPharma Dive541raps241onclive165fda recalls116
therapy area
allOncology12661Rare Disease3289Immunology2967Cardiology2833Hematology2240Pulmonology2217Vaccines
  • Emerging biotech hubs like India could help lower global drug costs by scaling development
    The article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…
    BioSpace · 13h agoNeutral↗ source
  • Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conference
    Biopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…
    BioSpace · 14h agoPositive↗ source
← prev
page 2 of 196
next →
fda medwatch112
globenewswire health73
fda press59
1822
Psychiatry & CNS1225
Ophthalmology1121
Endocrinology & Metabolism794
Pain784
Nephrology767
Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concerns
Novartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
BioSpace · 14h agoNegative readoutNegative↗ source
  • John Powers III named permanent director of NIAID after year-long vacancy
    The National Institute of Allergy and Infectious Diseases announced that its acting head, John Powers III, will become the institute’s permanent director. Powers, a physician‑scientist, has been w…
    STAT · 1h agoPositive↗ source
  • China adds CAR-T therapy to national insurance list, slashing price to $40,000
    China has added a CAR-T therapy to its National Reimbursement Drug List, cutting the price to $40,000. The reduction brings the treatment within the scope of basic medical insurance, improving aff…
    Endpoints · 2h agoRegulatoryNeutral↗ source
  • Canadian biotech firms turn to Europe as US political uncertainty creates new market opportunities
    At BIO-Europe in Cologne, Canadian companies said shifting US politics are prompting them to look to European partners. They highlight Canada’s regulatory speed and economic incentives as advantag…
    BioSpace · 4h agoPositive↗ source
  • CDC finds 10% of U.S. adults used GLP-1 drugs in 2025, 20% of them took compounded versions; Russia may seize foreign drug IP
    The Centers for Disease Control and Prevention reported that during July and August 2025 roughly one in ten U.S. adults said they had taken a GLP-1 medication at some point in the prior year. Amon…
    STAT · 4h agoNeutral↗ source
  • Democrats adopt "Medicare for More" as new health-care expansion message
    Democrats in the House have agreed on a new policy slogan, "Medicare for More," signaling a push to broaden health‑care coverage. The phrase is meant to set the agenda apart from the more ambitiou…
    STAT · 5h agoNeutral↗ source
  • San Diego’s Seawolf Therapeutics raises $100M to develop non-viral gene therapies for obesity, muscle loss and osteoporosis
    San Diego‑based Seawolf Therapeutics announced it has closed a $100 million financing round to fund its platform for non‑viral gene therapies. The company says its approach tackles a long‑standing…
    Endpoints · 9h agoDealPositive↗ source
  • New polymer lidding technologies aim to make pharmaceutical blister packs fully recyclable
    Pharmaceutical manufacturers are increasingly prioritizing sustainability in material selection, packaging design and end-of-life handling. The goal is to lower environmental impact while keeping p…
    BioPharma Dive · 9h agoPositive↗ source
  • BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 Ranking
    STAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…
    STAT · 9h agoNeutral↗ source
  • STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
    A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.
    STAT · 6h agoRegulatoryNeutral↗ source
  • Physician burnout persists as hospitals push self-care instead of systemic fixes
    In a new STAT+ column, former ENT surgeon Frances Mei Hardin reflects on the growing crisis of physician burnout and the limited impact of hospital‑mandated wellness programs. Hardin shares a pers…
    STAT · 9h agoNegative↗ source
  • BridgeBio's Morgan Paull and Christine Zhang Named BioSpace 40 Under 40, Emphasize Patient-Centric Model
    BridgeBio has seen two of its young executives, Morgan Paull and Christine Zhang, named to BioSpace’s 2026 40 Under 40 list. Their inclusion highlights the company’s rapid growth and focus on rare-…
    BioSpace · 13h agoPositive↗ source
  • Apple and OpenEvidence Begin Study of Experimental AI Health Chat App
    Apple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
    STAT · 17h agoNeutral↗ source
  • Parker Institute CEO Karen Knudsen says cancer research faces translation challenges
    Karen Knudsen, who has a track record of reshaping medical organizations, is now leading the Parker Institute for Cancer Immunotherapy, a nonprofit that turned ten years old this year. In a recent…
    Endpoints · 3h agoNeutral↗ source
  • Health-care providers turn to lawsuits over unpaid services as insurance costs squeeze paychecks
    Health-care providers are increasingly filing lawsuits to collect unpaid fees, according to a STAT+ newsletter that cites cases such as an air-ambulance company suing a plumber and a claim involvin…
    STAT · 2h agoNegative↗ source
  • VC John Doerr praises Tom Health AI tool as promising solution for primary care
    Venture capitalist John Doerr highlighted a new artificial-intelligence platform called Tom Health, noting its potential impact on primary-care delivery. Doerr, whose brother's name inspired the c…
    STAT · 8h agoPositive↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 1h agoLayoffsNegative↗ source
  • Kennedy's MAHA Initiative Gains Momentum with Stephen Miller as White House Chief of Staff
    Stephen Miller's recent appointment as White House chief of staff has been described as a catalyst for the health secretary's MAHA agenda. The move appears to have energized the initiative, accordi…
    STAT · 9h agoPositive↗ source
  • Proposal to start medical school after Step 1 exam to cut debt and boost diversity
    The authors, bioethicists at SUNY Upstate Medical University, argue that medical education should be split into two distinct phases. The first phase would cover the pre‑clinical sciences that are t…
    STAT · 9h agoPositive↗ source
  • STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC
    The supplement NAC has been widely available for years, but exists in a legal grey area.
    STAT · 15m ago↗ source
  • Helus Pharma notches successful Phase 3 depression readout
    Helus Pharma, part of the budding class of psychedelics companies, said its lead drug improved depression symptoms compared to placebo, but investors appeared slightly skittish about the safety pro…
    Endpoints · 39m ago↗ source
  • STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity
    How obesity medications may become the next big battleground over access to medicines in lower-income countries.
    STAT · 51m ago↗ source
  • FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entry
    The U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…
    BioSpace · 1d agoCRLNegative↗ source